Focus: PMV Pharma is a public oncology-focused biotech company specializing in p53 regulators, with 201-500 employees based in Princeton, NJ. The company is in early-stage clinical development with no approved products generating revenue.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow PMV Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from PMV Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for PMV Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
PMV Pharma appoints Philip Herman as CCO - The Pharma Letter
PMV Pharma appoints Philip Herman as CCO The Pharma Letter
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer - finance.yahoo.com
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer finance.yahoo.com
PMV Pharma's p53 drug rezatapopt hits 46% response rate in Phase 2 ovarian cancer readout - Dealroom
PMV Pharma's p53 drug rezatapopt hits 46% response rate in Phase 2 ovarian cancer readout Dealroom
PMV Pharma raises USD 50.8m to fund rezatapopt NDA submission in Q1 2027 - allsci.com
PMV Pharma raises USD 50.8m to fund rezatapopt NDA submission in Q1 2027 allsci.com
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push - finance.yahoo.com
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push finance.yahoo.com
PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants - Quiver Quantitative
PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants Quiver Quantitative
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo